UC, MIT Battle Over Patent to Gene-Editing Tool
By Lisa M. Krieger,
San Jose Mercury News
| 05. 09. 2015
Will the University of California reap the financial rewards of CRISPR's commercial use, likely worth billions of dollars? That's the source of a bitter fight.
In June 2012, UC Berkeley's Jennifer Doudna and Emmanuelle Charpentier, now a professor in Germany, showed how bacteria's natural defense system could be turned into a "gene editing" tool to cut DNA strands.
Seven months later, Feng Zhang of the Massachsuetts Institute of Technology, along with Harvard's George Church, showed that the tool also works in human cells.
UC and Doudna filed for a patent first. But in a shocking turn of events, MIT and Zhang won last month, earning the patent that covers use of CRISPR in every species except bacteria, including humans.
MIT paid extra to expedite Zhang's patent application. MIT and Zhang also assert that the patent belongs to them because Doudna didn't prove it works in human cells, only bacterial cells.
Zhang also submitted photos of lab notebooks showing his lab work was ahead of Doudna's.
UC and Doudna are fighting back, submitting thousands of pages of documentation to support their...
Related Articles
By Tania Fabo, Truthout | 02.28.2026
The reproductive tech company Orchid recently launched a genetic test that promises a whole genome sequencing report for embryos. It is the first such test commercially available to couples undergoing in vitro fertilization (IVF) and claims to detect things like...
By Jenn White, NPR | 02.26.2026
By Vittoria Vardanega, SWI swissinfo.ch | 02.13.2026
In recent years, sperm donation has produced family trees of unprecedented size, stretching across countries and, in some cases, continents. Stories of “mass donors” have captured public attention, most recently through the Netflix documentary series, The Man with 1,000 Kids...
By Ava Kofman, The New Yorker | 02.09.2026
1. The Surrogates
In the delicate jargon of the fertility industry, a woman who carries a child for someone else is said to be going on a “journey.” Kayla Elliott began hers in February, 2024, not long after she posted...